For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 38 | 275 | 4,048 | |
| General and administrative | 259 | 213 | 514 | |
| Total operating expenses | 297 | 488 | 4,562 | |
| net operating loss | -297 | -488 | -4,562 | |
| Change in fair value of warrant and derivative liabilities | - | -315 | - | |
| Loss on convertible debt conversions | - | -43 | - | |
| Interest expense | - | 130 | 35 | |
| Total other income (expense) | 27 | -488 | -35 | |
| Net loss | -270 | -976 | -4,597 | |
| Basic EPS | - | - | -0.55 | |
| Diluted EPS | -0.03 | -0.11 | -0.55 | |
| Basic Average Shares | - | - | 8,308,000 | |
| Diluted Average Shares | 9,342,000 | 8,521,000 | 8,308,000 | |
BIO-PATH HOLDINGS, INC. (BPTH)
BIO-PATH HOLDINGS, INC. (BPTH)